Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04857372 · ClinicalTrials.gov registry record · Phase 1

A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors

A Phase 1 study of Mesothelioma, sponsored by Novartis Pharmaceuticals.

Active
Registry status
Phase 1
Development phase
137
Enrollment target
16
Study locations

NCT04857372 is a Phase 1 study of Mesothelioma that is active but no longer recruiting, run by Novartis Pharmaceuticals. The registered enrollment target is 137 participants, below the 195-participant average among 46 other Mesothelioma trials with a reported enrollment target (30% lower). The trial reports 16 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04857372, a Phase 1 study of Mesothelioma, is active but no longer recruiting, sponsored by Novartis Pharmaceuticals.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
137 participants
Enrollment target
16
Study locations

Study Summary

The purpose of this study is to characterize the safety and tolerability of IAG933 in patients with mesothelioma, NF2/LATS1/LATS2 mutated tumors and tumors with functional YAP/TAZ fusions and to identify the maximum tolerated dose and/or recommended dose.

Conditions Studied

Mesothelioma

Interventions

  • DRUG IAG933

Study Locations (16)

Other

  • Novartis Investigative Site - Villejuif
  • Novartis Investigative Site - Essen
  • Novartis Investigative Site - Zurich
  • Novartis Investigative Site - Manchester

MI

  • Novartis Investigative Site - Milan
  • Novartis Investigative Site - Rozzano

California

  • University of California LA - Los Angeles

Illinois

  • Uni of Chi Medi Ctr Hema and Onco - Chicago

Massachusetts

  • Massachusetts General Hospital - Boston

Ohio

  • Cleveland Clinic Foundation - Cleveland

Texas

  • MD Anderson Cancer Center - Houston

Victoria

  • Novartis Investigative Site - Melbourne

Trial Details

FieldValue
Enrollment Target 137 participants
Start Date 2021-10-21
Est. Completion 2026-09-04
Phase Phase 1

Sponsor

Novartis Pharmaceuticals

1,375 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04857372

The ClinicalTrials.gov registry entry for NCT04857372 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 137 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 195-participant average among 46 other Mesothelioma trials with a reported enrollment target (30% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Mesothelioma appearing as the primary indexed condition, and to 1 intervention - of which IAG933 is the first listed.

NCT04857372 reports 16 study locations spanning 12 distinct geographic areas - top geographies include Other, MI, California.

Frequently Asked Questions

What is clinical trial NCT04857372 about?

NCT04857372 is a clinical study titled "A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors". The purpose of this study is to characterize the safety and tolerability of IAG933 in patients with mesothelioma, NF2/LATS1/LATS2 mutated tumors and tumors with functional YAP/TAZ fusions and to identify the maximum tolerated dose and/or recommended dose.

What is the current status of trial NCT04857372?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 137 participants. The study started on 2021-10-21. Estimated completion is 2026-09-04.

What conditions does trial NCT04857372 study?

This clinical trial studies the following conditions: Mesothelioma.

What interventions are being tested in trial NCT04857372?

The interventions under investigation include: IAG933 (DRUG).

Who is sponsoring clinical trial NCT04857372?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04857372 being conducted?

This trial has 16 study locations across California, Illinois, Massachusetts, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Mesothelioma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Mesothelioma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.